Evaluating the 'real' cost-effectiveness of health technology: Reconciling the public interest with patients' interests

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 1, 2007, Pages

  Dixon, Simon ^a   Peters, John R ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Detemir; Diabetes, type 1 and 2; Glargine; Hypoglycaemia; Insulin analogues; Neutral protamine hagedorn insulin (NPH)

Indexed keywords

INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SCREENING; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; GENERAL PRACTICE; GOLD STANDARD; HEALTH CARE SYSTEM; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PUBLIC HEALTH SERVICE; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; UNITED KINGDOM;

EID: 33947408216     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X167552     Document Type: Review

References (29)

1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001;4:225-50
2. Raftery JP. Review of NICE's recommendations, 1999-2005. BMJ 2006;332:1266-8
3. Dillon A. Letter to manufacturers regarding transfer to STA process. NICE, 29 November 2005 Available at: www.nice.org. uk/download.aspx?o= 281942〉 (last accessed: 25th July 2006)
4. McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S17-19
5. McEwan P, Poole CD, Tetlow T, et al. Evaluation of the cost effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23(Suppl 1):S21-31
6. Rothwell PM. External validity of randomised controlled trials: 'To whom do the results of this trial apply?' Lancet 2005;365:82-93
7. Currie CJ, Poole CD, Tetlow T, et al. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S33-39
8. Poole CD, Tetlow T, McEwan P, et al. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23(Suppl 1):S41-48
9. Pieber TR, Treichel HC, Robertson LI, et al. Detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. Diabetologia 2005;48(Suppl 1):A92-2
10. Warren E, Weatherly-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45):iii, 1-57
11. Currie CJ, Morgan CLl, Poole CD, et al. Multivariate models of health related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
12. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80
13. The DCCT Study Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450-9
14. NICE. Guide to the single technology appraisal (STA) process (Interim process). 11 November 2005. Available from: www. nice.org.uk/page.aspx?o=278616 [Last accessed 25 April 2006]
15. NICE. The guidelines manual - Chapter 7: Reviewing and grading the evidence. London: NICE, 2006
16. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6
17. NICE. The guidelines manual - Chapter 8: Incorporating health economics in guidelines and assessing resource impact. London: NICE, 2006
18. Centre for Reviews and Dissemination, University of York. Available from: www.york.ac.uk/inst/crd [Last accessed: 20 July 2006]
19. Drummond M, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991;7:561-73
20. O'Brien B. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials. Medical Care 1996;34 (12 Suppl):DS99-108
21. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a 'trial effect.' J Clin Epidemiol 2001;54:217-24
22. National Institute for Clinical Excellence. Appraisal Consultation Document: The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes. Available at: www. nice.org.uk/page.aspx?o=35497 [Last accessed: 25 October 2005]
23. Misbin RI. Medical Review of detemir (NDA 021-536). Centre for Drug Evaluation & Research, US Food and Drug Administration. 9th June 2005. 〈http://www.fda.gov/cder/foi/nda/2005/021-536_Levemir_medr.PDF〉 (last accessed: 20th June 2006)
24. Insulin detemir (rys) cartridge 3 mL (Penfill), prefilled device 3 mL (FlexPen), 100 U/mL, Levemir , July 2005. Department of Health and Government, Australia. Available at: www. health.gov.au/internet/wcms/publishing.nsf/ Content/pbac-psd-insulind [Last accessed 4 May, 2006]
25. Russmann A, Schreiber S. Treatment with insulin glargine of patients with type 1 diabetes in clinical practice: metabolic control over 30 months. Diabetologia 2004;47(Suppl. 1): [Abstract 842]
26. Schreiber, S, Russmann, A. Treatment with insulin glargine of patients with type 2 diabetes in clinical practice: metabolic control over 30 months. Diabetologia 2004;47(Suppl 1): A271 [Abstract 748]
27. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002;324:1577-80
28. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycemia: the size of the problem. Diabetes Metab Res Rev 2004;20(Suppl 2):S32-42
29. Insulin Glargine, injection, 100 units per mL, 10 mL vials and 3 mL x 5 cartridges, Lantus® , July 2005. Department of Health and Government, Australia. Available from: www. health.gov.au/internet/wcms/publishing.nsf/ Content/pbac-psd-insulin [Last accessed 4 May, 2006]